Author:
Jordan Karin,Blättermann Luisa,Hinke Axel,Müller-Tidow Carsten,Jahn Franziska
Publisher
Springer Science and Business Media LLC
Reference31 articles.
1. ABIM (2013) Choosing wisely: ten things physicians and patients should question.
http://www.choosingwisely.org/doctor-patient-lists/american-society-of-clinical-oncology
in: editor (ed)^(eds) Book choosing wisely: ten things physicians and patients should question.
http://www.choosingwisely.org/doctor-patient-lists/american-society-of-clinical-oncology
City
2. Aridome K, Mori SI, Baba K, Yanagi M, Hamanoue M, Miyazono F, Tokuda K, Imamura H, Ogura Y, Kaneko K, Kijima F, Maemura K, Ishigami S, Natsugoe S (2016) A phase II, randomized study of aprepitant in the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapies in colorectal cancer patients. Mol Clin Oncol 4:393–398
3. Escobar Y, Cajaraville G, Virizuela JA, Alvarez R, Munoz A, Olariaga O, Tames MJ, Muros B, Lecumberri MJ, Feliu J, Martinez P, Adansa JC, Martinez MJ, Lopez R, Blasco A, Gascon P, Calvo V, Luna P, Montalar J, Del Barrio P, Tornamira MV (2015) Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (actual data of vomiting incidence by chemotherapy evaluation) study. Support Care Cancer 23:2833–2840
4. Gralla R, Jordan K, Rapoport B, Street JC, Carides A (2010) Assessing the magnitude of antiemetic benefit with the addition of the NK1 receptor antagonist (NK1) aprepitant for all platinum agents: analysis of 1,872 patients (pts) in prospective randomized clinical phase III trials (RCTs). J Clin Oncol 28:9057
5. Hesketh PJ (1997) Methodology of antiemetic trials. Consensus conference on antiemetic therapy Extanded abstract book, Perugia, Italy April 28-29: 135–141